Search

This letter to the editor discusses the real-life experience of using the long-acting cabotegravir-rilpivirine combination for the treatment of HIV in a person with detectable viremia. The combination allows for once-a-month dosing and may address issues of pill burden and non-compliance. The letter describes the case of a 49-year-old woman with a history of poor adherence to treatment and follow-up. After switching to the cabotegravir-rilpivirine combination, the patient experienced good tolerability and achieved virological suppression within 12 weeks. The authors suggest that this long-acting regimen may be a viable option for individuals who struggle with daily dosing. [Extracted from the article]

Regimens containing darunavir are one of the first one with two drugs that demonstrated good efficacy as a simplification strategy. We wanted to describe the characteristics of patients followed in our center on a dual therapy regimen containing darunavir evaluating the metabolic aspects during follow-ups. We collected data from 208 patients switching to lamivudine plus darunavir with either ritonavir or cobicistat between 2010 and 2019. In all patients we found an increase in low-density lipoprotein (LDL), with no rising in creatinine, total cholesterol, or triglycerides. Twenty-five patients reached 120 weeks of follow-up. In these patients, no significant metabolic changes were described without concomitant treatment with drugs for dyslipidemia. These regimens seem to be more tolerable in metabolic profile compared with the data concerning three-drug therapies, leading only to a slight increase in LDL. The main reason for discontinuation was for a single-tablet therapy. None of the patients started treatment for dyslipidemia. [ABSTRACT FROM AUTHOR]

Aim of this study is to assess the impact of doravirine (DOR)-based regimens on cardiovascular risk in treatment-experienced people living with HIV (PLWHIV). We retrospectively analyzed a cohort of 40 treatment-experienced PLWHIV switching to a DOR-based three-drug regimen, evaluating 10-year risk of manifesting clinical cardiovascular diseases (CD) through the Framingham Risk Score at baseline, 12, and 24 weeks of follow-up. At baseline, median predicted 10-year risk of cardiovascular disease (10Y-CD) was 8.0% (interquartile range 4.0–13.0). After 12 weeks, we observed a significant reduction in 10Y-CD (mean decrease −2.21, p = .012); similarly, we observed a nonsignificant reduction at week 24 (p = .336). Regarding metabolic parameters, after 24 weeks we observed a significant reduction in total cholesterol (median change −8.8 mg/dL, p = .018), low-density lipoprotein cholesterol (median −9.5 mg/dL, p = .007), and triglycerides (median −19.8 mg/dL, p < .001). Our results show a favorable metabolic impact of DOR-based regimens along with a promising reduction in 10-year risk of cardiovascular disease. [ABSTRACT FROM AUTHOR]